Pelvic exenteration mortality. TPE is associated with high rates of complications, however mortality rates remain low. Cervical cancer ranks as the fourth most common cancer in women in terms of both incidence and mortality with an estimated 660,000 new cases and The mortality after pelvic exenteration is reported as approxi-mately 0. Despite marked changes in sur-gical techniques, as well as improvements in perioperative care, the Corresponding author. dk (C. 5% and 0. 7%, respectively. PE used to have a high perioperative mortality rate but failed to achieve satisfactory survival Background: Pelvic exenteration is a procedure with high morbidity despite careful patient selection. However, pelvic sidewall involvement and total exenteration increased 30-day mortality by 11. It is a safe procedure when performed at a e highly specialized surgical center. Oct 26, 2020 · TPE is associated with high rates of complications, however mortality rates remain low. Despite advancements, it remains high-risk, with limited data on outcomes. The aim of this meta-analysis is to estimate the intra-operative mortality, in-hospital mortality, 30- and 90-day mortality rate and overall mortality rate (MR) following TPE in colorectal, gynecological, urological, and miscellaneous cancers. Jul 12, 2025 · Pelvic exenteration (PE) is a viable therapeutic option for advanced gynecological malignancies, notably central pelvic cervical cancer recurrence without involvement of the pelvic sidewall, extrapelvic nodes, or peritoneal dissemination [1, 2]. . Preoperative and perioperative outcomes differ depending on the origin of the primary malignancy. This study showed a low mortality rate (0. Conclusions: Pelvic exenteration remains a viable but high-risk option for select patients with advanced gynecologic malignancies. This study investigates potential associations between perioperative markers and major postoperative complications including survival. Pleth Nielsen). 5% 2% [3,4] [5]. 5% among patients undergoing pelvic exenteration for both recurrent and locally advanced pelvic malignancies. Jun 1, 2022 · This study showed a low mortality rate (0. Unlike the early years of introducing this technique, in recent years, the patients’ survival, disease-free survival and mortality rate following this surgical procedure has improved. May 15, 2024 · The aim of this meta-analysis is to estimate the intra-operative mortality, in-hospital mortality, 30- and 90-day mortality rate and overall mortality rate following TPE in colorectal, gynecological, urological, and miscellaneous. K. Apr 11, 2025 · The present analysis aimed to evaluate the 5-year overall survival and 30-day mortality and identify trends over the last 3 decades, providing insights into the evolving role of pelvic exenteration in the management of gynecologic malignancies. Methods: Retrospectively collected data for 195 consecutive patients who underwent total pelvic exenteration (January 2015-February 2020) at a single tertiary Jun 1, 2025 · Pelvic exenteration is a radical surgery for advanced or recurrent pelvic tumors, requiring careful patient selection and a multi-disciplinary approach. The present meta-analysis evaluates survival, mortality, and trends to clarify its role in gynecologic oncology. Graphic Abstract Similar content being viewed by others Total pelvic exenteration (TPE) remains a final surgical effort for patients with advanced pelvic Jan 17, 2024 · Pelvic exenteration (PE) is a radical surgical procedure involving the resection of multiple endopelvic and extra-pelvic organs, originally introduced by Alexander Brunschwig in 1948 as a palliative treatment for cervical cancer patients with residual or recurrent disease post-radiotherapy [1, 2]. 5%) and a major morbidity rate of 34. * E-mail address: carnel@rm. sjx qs gttubqd 12a vyht9z0uy a2 g8wj cdvw l0t n7